New Jersey

  • August 11, 2009

    BMW Settles Defective-Subframe Class Action

    BMW of North America LLC has received the green light to settle a class action accusing the automaker of manufacturing defective subframes that caused some vehicles to crack near the trunk floor, forcing owners to shell out costly repair fees.

  • August 11, 2009

    Verizon's Bid To Dismiss VoIP Patent Suit Denied

    A district judge has denied a motion by Verizon Communications Inc. to dismiss for lack of personal jurisdiction a suit claiming Verizon infringed on a patent for Voice Over Internet Protocol technology.

  • August 10, 2009

    Q&A With Covington & Burling's Rob Fram

    As the Eastern District of Texas has become quite crowded and the possibility of obtaining an injunction has dimmed for such plaintiffs, the ITC appears to be the new forum of choice for high-stakes cases, says Rob Fram, co-chair of Covington & Burling LLP's intellectual property litigation group.

  • August 7, 2009

    NY Gov. Signs Executive Order To Reduce Emissions

    New York Gov. David A. Paterson has signed an executive order establishing a goal to reduce greenhouse gas emissions in the state by 80 percent below 1990 levels over the next four decades.

  • August 7, 2009

    AT&T Option Coverage Suit Rightly Tossed: Court

    A New Jersey appeals court has affirmed motions to dismiss in AT&T Corp.'s coverage suit against two separate fiduciary insurance programs over litigation stemming from adjustments to a stock option plan issued to former MediaOne Group Inc. executives following the AT&T-MediaOne merger.

  • August 7, 2009

    Fuji Defendants Ask Court To Stay $16M Award

    About two weeks after a judge ordered them to cough up more than $16 million to Fujifilm Corp., the defendants in a long-standing patent fight have asked a judge to stay the monetary judgment pending appeal.

  • August 6, 2009

    Wyeth, Pfizer Resolve Investor Suits Over Merger

    Wyeth Inc. and Pfizer Inc. have reached a deal to settle several shareholder lawsuits seeking to block the $68 billion merger between the pharmaceutical giants.

  • August 6, 2009

    Blank Rome Snags Sonnenschein Bankruptcy Partner

    Blank Rome LLP has bolstered its new Los Angeles office with the addition of Sara Chenetz as a partner to the firm's business restructuring and bankruptcy group.

  • August 6, 2009

    Exxon, DuPont Sue Alumax Over NJ Landfill Cleanup

    Rohm & Haas Co., DuPont Co., Exxon Mobil Corp. and others have amended a lawsuit against aluminum hardware company Alumax Inc. over the cleanup of a New Jersey landfill in light of a 2007 U.S. Supreme Court decision that expanded the possible causes of action for plaintiffs under the Superfund law.

  • August 6, 2009

    Q&A With Jackson Lewis' Vincent Cino

    An employer that prevails in a frivolous case should have the right to recoup its legal fees. In most instances, this will not be feasible, but it may serve as a deterrent to the filing of cases that should never see the light of day, says Vincent Cino, practice group leader of Jackson Lewis LLP's litigation group.

  • August 6, 2009

    3rd Circ. Vacates Cert. In Tanning UV Warning Suit

    An appeals court has vacated class certification in a lawsuit accusing salon franchise Hollywood Tanning Systems Inc. of distorting the benefits of indoor tanning and failing to provide adequate warnings on exposure to ultraviolet light.

  • August 5, 2009

    C&D Appeals $29.2M Award In Pregnancy Test Suit

    A week after Abbott Laboratories appealed the $29.2 million infringement verdict against it for allegedly infringing Church & Dwight Co.'s patent for home pregnancy tests, C&D filed a cross-appeal of orders Wednesday denying its motions for attorneys' fees and treble damages.

  • August 5, 2009

    Urethane Plaintiffs Seek Non-US Commerce Docs

    Plaintiffs suing BASF Corp., Huntsman International LLC and The Dow Chemical Co. over an alleged antitrust conspiracy in the urethane market are asking the judge overseeing the multidistrict litigation to force those companies to fork over documents related to commerce outside the United States.

  • August 5, 2009

    Fed. Circ. Affirms Invalidity Of Bayer's Yasmin Patent

    A federal appeals court has upheld a ruling that invalidated the patent for Bayer Schering Pharma AG's oral contraceptive Yasmin in a dispute with Barr Laboratories Inc. over a generic version of the drug.

  • August 5, 2009

    Merck, Schering Offer $42M To Settle Vytorin Suits

    Pharmaceutical giants Merck & Co. and Schering-Plough Corp. have said they will pay $41.5 million to settle a host of civil lawsuits over joint marketing and studies of the cholesterol drug Vytorin.

  • August 5, 2009

    Covidien Loses Bid To Block Generic Restoril

    Covidien Ltd. has been thwarted in its attempt to block URL Pharma Inc. from launching a generic version of the sleep disorder drug Restoril when a U.S. Food and Drug Administration stay expires later in August.

  • August 5, 2009

    J&J Unit Eyed Over Clinical Reviewers

    New Jersey's attorney general has issued a subpoena to Johnson & Johnson's DePuy Orthopaedics Inc. subsidiary seeking information regarding the financial interests of clinical investigators who performed studies for the unit and DePuy Spine Inc.

  • August 5, 2009

    Naked Cowboy, Clear Channel Drop Trademark Suit

    The Times Square street entertainer known as the Naked Cowboy has agreed to drop a lawsuit accusing Clear Channel Communications Inc. of infringing his trademarked persona when one of its radio stations posted videos featuring a Naked Cowboy impostor on YouTube.

  • August 4, 2009

    Navinta Infringed Abraxis' Naropin Patents: Judge

    Generic-drug manufacturer Navinta LLC has been found liable for infringing three patents for Abraxis BioScience Inc.'s injectable pain management drug Naropin.

  • August 4, 2009

    Daiichi Earns Win Against Mylan Over Benicar Patent

    A federal judge has ruled that Mylan Pharmaceuticals Inc. infringed Daiichi Sankyo Co. Ltd.'s patent for the active ingredient in Benicar when Mylan tried to market a generic version of the hypertension drug.